Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab + axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma
MOH_2017-04-20_000321Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Feb 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in renal cell carcinoma (RCC) comparing Avelumab + axitinib with Sunitinib (2 arms). Started Feb 2016; status: recruiting.
02
Drugs
avelumabaxitinibsunitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on MOH_2017-04-20_000321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-04-20_000321.